@weight.shifter's Wegovy plateau struggles, fact-checked
Quick answer
Semaglutide (Wegovy) is a GLP-1 receptor agonist that slows gastric emptying and suppresses appetite for weight management. Clinical trials show most weight loss occurs in the first 60 weeks, followed by plateau periods where patients maintain rather than continue losing weight. Discontinuation typically leads to rapid weight regain.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
@weight.shifter describes experiencing a weight loss plateau lasting months while on Wegovy, along with returning food cravings and "food noise." They're questioning whether to continue the medication given these challenges and the financial cost.
The creator doesn't make specific medical claims but expresses frustration with diminished effectiveness. This represents a common experience among GLP-1 users who initially see dramatic results.
Are weight loss plateaus normal on Wegovy?
Yes, plateaus are completely normal and expected with semaglutide treatment. The STEP 1 trial (Wilding et al., NEJM, 2021) showed that while participants achieved 14.9% weight loss at 68 weeks, most of the loss occurred in the first 60 weeks, with minimal additional loss afterward.
The STEP 5 trial demonstrated this plateau effect over 104 weeks. Participants maintained their weight loss but didn't continue losing significantly after the first year. This doesn't mean the drug stopped working. It means your body reached a new equilibrium weight.
What @weight.shifter describes as "food noise" returning matches clinical observations. Some patients report that the appetite suppression effects can diminish over time, though this varies widely between individuals.
Should you stop Wegovy during a plateau?
The data suggests stopping is usually a mistake. The STEP 1 withdrawal study found that participants who discontinued semaglutide regained 66% of their lost weight within 20 weeks.
More relevant to @weight.shifter's situation: the STEP 5 extension study showed that people who continued treatment maintained their weight loss even during plateau periods. Those who stopped treatment consistently regained weight.
Financial concerns are valid since Wegovy costs around $1,300 monthly without insurance. But if you can afford it and you've achieved meaningful weight loss, the evidence supports continuation for weight maintenance rather than hoping for continued dramatic losses.
What are the options during a plateau?
Your doctor might consider several approaches, though none are guaranteed to restart dramatic weight loss. Dose optimization sometimes helps, though many patients are already on the maximum 2.4mg weekly dose.
Some physicians discuss switching to tirzepatide (Mounjaro/Zepbound), which showed superior weight loss in head-to-head comparisons. The SURMOUNT-2 trial found 15.7% weight loss with tirzepatide versus 3.3% with placebo at 72 weeks.
Lifestyle interventions become more important during plateaus. The medications work best combined with dietary changes and exercise, not as standalone solutions. @weight.shifter doesn't mention whether they've adjusted these factors.
What should you actually know?
Weight loss plateaus don't mean Wegovy has stopped working. The drug continues suppressing appetite and slowing gastric emptying even when the scale doesn't move. Think of it as weight maintenance medication during plateau periods.
The "sweet tooth coming back" that @weight.shifter mentions is real. Some patients develop tolerance to the appetite suppression effects, though this isn't universal. Clinical studies show wide individual variation in response duration.
Most importantly, don't make medication decisions based on short-term frustration. The clinical trials tracked patients for 1-2 years specifically because plateaus are normal parts of the weight loss journey with GLP-1 medications.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @weight.shifter's Wegovy plateau struggles, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Semaglutide (Wegovy) is a GLP-1 receptor agonist that slows gastric emptying and suppresses appetite for weight management.
FormBlends verdict
Semaglutide (Wegovy) is a GLP-1 receptor agonist that slows gastric emptying and suppresses appetite for weight management. Clinical trials show most weight loss occurs in the first 60 weeks, followed by plateau periods where patients maintain rather than continue losing weight. Discontinuation typically leads to rapid weight regain.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide (Wegovy) is a GLP-1 receptor agonist that slows gastric emptying and suppresses appetite for weight management. Clinical trials show most weight loss occurs in the first 60 weeks, followed by plateau periods where patients maintain rather than continue losing weight. Discontinuation typically leads to rapid weight regain.
- Weight loss plateaus after 60 weeks are normal with Wegovy, as shown in the STEP 1 trial where participants maintained but didn't continue losing weight
- Stopping semaglutide during plateaus typically leads to rapid weight regain, with patients regaining 66% of lost weight within 20 weeks
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Weight loss plateaus after 60 weeks are normal with Wegovy, as shown in the STEP 1 trial where participants maintained but didn't continue losing weight
- Stopping semaglutide during plateaus typically leads to rapid weight regain, with patients regaining 66% of lost weight within 20 weeks
- Some patients experience returning food cravings over time, though appetite suppression effects vary widely between individuals
- Wegovy functions as weight maintenance medication during plateau periods, continuing to suppress appetite even when the scale doesn't move
- Tirzepatide showed superior weight loss (15.7% vs 3.3% placebo) in SURMOUNT-2 and may be an option for patients plateauing on semaglutide
- The medication works best combined with lifestyle changes rather than as a standalone solution for long-term weight management
- Clinical trials followed patients for 1-2 years specifically because plateaus are expected parts of the GLP-1 weight loss journey
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Weight Shifter · TikTok creator
60.4K views on this video
Plateau for months now. Sweet tooth coming back. Food noise hitting me. Just feel I’m wasting money on Wegovy. Do I give it more time? #oceanwaves #stalled #weighloss #wegovy #mounjaro
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Weight Shifter, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.